JP2010536858A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536858A5
JP2010536858A5 JP2010521913A JP2010521913A JP2010536858A5 JP 2010536858 A5 JP2010536858 A5 JP 2010536858A5 JP 2010521913 A JP2010521913 A JP 2010521913A JP 2010521913 A JP2010521913 A JP 2010521913A JP 2010536858 A5 JP2010536858 A5 JP 2010536858A5
Authority
JP
Japan
Prior art keywords
compound
effective amount
therapeutically effective
patient
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010521913A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536858A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/070943 external-priority patent/WO2009025958A1/en
Publication of JP2010536858A publication Critical patent/JP2010536858A/ja
Publication of JP2010536858A5 publication Critical patent/JP2010536858A5/ja
Pending legal-status Critical Current

Links

JP2010521913A 2007-08-22 2008-07-23 エリスロポエチン受容体ペプチド製剤及び用途 Pending JP2010536858A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95739607P 2007-08-22 2007-08-22
US98975807P 2007-11-21 2007-11-21
PCT/US2008/070943 WO2009025958A1 (en) 2007-08-22 2008-07-23 Erythropoietin rceptor peptide formulations and uses

Publications (2)

Publication Number Publication Date
JP2010536858A JP2010536858A (ja) 2010-12-02
JP2010536858A5 true JP2010536858A5 (https=) 2011-10-20

Family

ID=40194013

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010521913A Pending JP2010536858A (ja) 2007-08-22 2008-07-23 エリスロポエチン受容体ペプチド製剤及び用途
JP2010521912A Pending JP2010536857A (ja) 2007-08-22 2008-07-23 エリスロポエチン受容体ペプチドの製剤及び使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010521912A Pending JP2010536857A (ja) 2007-08-22 2008-07-23 エリスロポエチン受容体ペプチドの製剤及び使用

Country Status (3)

Country Link
EP (1) EP2195002A4 (https=)
JP (2) JP2010536858A (https=)
WO (2) WO2009025958A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9422338B2 (en) 2011-05-19 2016-08-23 Epodose Llc Compounds that bind to the erythropoietin receptor
EP3148522A4 (en) * 2014-05-28 2018-01-10 The Board of Regents of The University of Texas System Novel compounds supports hematopoietic stem cells and red blood cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4266028B2 (ja) * 2003-05-12 2009-05-20 アフィーマックス・インコーポレイテッド エリスロポエチン受容体に結合する新規ペプチド
SI1625156T1 (sl) * 2003-05-12 2013-02-28 Affymax, Inc. Peptidi, ki se veĹľejo k eritropoetinskemu receptorju
US7919461B2 (en) * 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP1902032A1 (en) * 2005-06-22 2008-03-26 Astex Therapeutics Limited Pharmaceutical compounds

Similar Documents

Publication Publication Date Title
JP6738376B2 (ja) 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
JP2012067116A5 (https=)
JP2009536191A5 (https=)
US20150342872A1 (en) Use of Paclitaxel Particles
JP2006507308A5 (https=)
JP2008542399A5 (https=)
US20130122111A1 (en) Method for treatment of advanced solid tumors
US20140356315A1 (en) Triblock copolymer and use therefor
JP2017025086A (ja) 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法
Colleoni et al. A phase II study of mitoxantrone combined with beta‐interferon in unresectable hepatocellular carcinoma
JP2010536858A5 (https=)
Seymour et al. A novel dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate)-neocarzinostatin] in the treatment of primary hepatocellular carcinoma.
JP2021535163A5 (https=)
WO2002083154A1 (en) Use of cationic dextran derivatives for protecting dose-limiting organs
RU2440113C2 (ru) Фармацевтическая композиция для инъекционного особенно целенаправленного местного применения
CN1168452C (zh) 甲氧基吗啉代阿霉素在制备治疗肝肿瘤的药物方面的应用
AU2013226944B2 (en) Inhibitory agent for body cavity fluid accumulation
JP2010521488A5 (https=)
CN120393051A (zh) 一种基于介孔聚多巴胺的靶向纳米系统及其制备方法和应用
RU2406539C2 (ru) Способ лечения хронической почечной недостаточности
WO2023182317A1 (ja) ボロン酸含有修飾ポリロタキサン
CN121243354A (zh) 同时诱导铜死亡和双硫死亡的靶向纳米药物
CN118354772A (zh) 治疗头颈癌的方法
Noda et al. Future Interventional Oncology Catheter-Based Therapies
Takahashi et al. Intra-arterial chemotherapy for muscle-invasive urinary bladder cancer.